Terminal de consulta web

Phase I study of the novel antifungal agent dapaconazole (zilt®) in healthy volunteers

Phase I study of the novel antifungal agent dapaconazole (zilt®) in healthy volunteers

T. Gagliano-Juca, M.F. Sampaio, A. Arruda, G. De Nucci, A.G. Lopes

ARTIGO

Inglês

The study aims to evaluate the tolerability of multiple-dose topical dapaconazole tosylate, a new imidazole antiftmgal drug, in healthy vohmteers. Twenty-four healthy vohmteers (12 men) with skin pigmentation classified as I-III in the Fitzpatrick scale emolled in this open-label, two-treatment... Ver mais

fechado

Phase I study of the novel antifungal agent dapaconazole (zilt®) in healthy volunteers

T. Gagliano-Juca, M.F. Sampaio, A. Arruda, G. De Nucci, A.G. Lopes

										

Phase I study of the novel antifungal agent dapaconazole (zilt®) in healthy volunteers

T. Gagliano-Juca, M.F. Sampaio, A. Arruda, G. De Nucci, A.G. Lopes

    Fontes

    International journal of pharmacology (Fonte avulsa)